PathAI has announced the latest update to AISight DX, its cloud-based digital pathology image management system, which now benefits from new capabilities for tumour board presentations, consult workflows, and voice-enabled reporting.
Built to support both laboratory operations and translational research, this release empowers teams to accelerate case organisation, collaborate in real time, and reduce friction in daily diagnostic workflows.
AISight Dx v2.17 delivers a redesigned queueing system integrated with AISight Live to help laboratories efficiently build, save, and share curated slide and case sets for tumour boards, education, and training. Highlights include proactive case suggestions, automatic queueing from accession pages, bulk add for cases or slides, drag and drop with reordering, grouping by metadata (eg case) with folder parity, item nicknames, and shareable saved queues in a new Library > Queues tab, enabling users to create dynamic, ready-for-presentation queues in advance for tumour boards, teaching sessions, and other use cases.
Also added is an optional, laboratory-configurable secondary review workflow. Laboratories can keep using the informal mentions and notifications approach or enable a structured flow. When enabled, the case assignment dashboard includes a Secondary reviewer column to assign pathologists; assignees see a Mark Viewed control in the slide viewer; viewed or un-viewed status appears on hover in the Secondary reviewer column; and assignment and viewing alerts appear in the notification centre. This provides a more formal, standardised process for consults while preserving laboratory flexibility.
Through a new collaboration with Voicebrook, AISight Dx supports speech-driven dictation and structured reporting within the AISight Dx workflow, helping pathologists reduce manual entry and maintain diagnostic flow. The compatibility is designed to connect slide review in AISight Dx with Voicebrook’s voice-enabled tooling, which supports dictation and voice commands. This capability is built for pathologists and focuses on reporting by voice within anatomic pathology workflows.
“AISight Dx v2.17 is built to make tumour boards and consults simpler and more effective, while giving pathologists finer-grained control over how they interact with algorithm results,” said Andy Beck MD PhD, CEO and Co-Founder of PathAI.“With presentation queues, a flexible consult workflow, and annotation insights, teams can prepare, present, and collaborate with greater confidence and speed.”
AISight Dx is FDA-cleared for primary diagnosis in the US , and is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland.